DRUG-INDUCED OSTEONECROSIS OF THE JAWS

Download full text PDF
Issue: 
3
Year: 
2015

E. Basin, Candidate of Medical Sciences; Professor Yu. Medvedev, MD; K. Polyakov, Candidate of Medical Sciences I.M. Sechenov First Moscow State Medical University

The paper gives an update on jaw osteonecrosis occurring with the use of different drugs.
Keywords: 
osteonecrosis
phosphorus osteonecrosis
bisphosphonates

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Majman G.M. Klinika i patogenez hronicheskoj fosfornoj intoksiktsii // Gor'kovskij med. zhurn. – 1934; 4–5: 81–105.
  2. Bruns G.F. Fosfornoe omertvenie litsevyh kostej // Vrach. – 1880; 1 (47): 772; 1 (49): 804–7; 1 (50): 829–35.
  3. Ruggiero S., Dodson T., Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw – 2014 Update // J. Oral Maxillofac. Surg. – 2014; doi: 10.1016/j.joms.2014.04.031.
  4. Hillner B., Ingle J., Chlebowski R. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer // J. Clin. Oncol. – 2003; 21: 4042.
  5. Saad F., Gleason D., Murray R. et al:. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma // J. Natl. Cancer Inst. – 2002; 94: 1458.
  6. Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. – 2004; 96: 879.
  7. Rosen L., Gordon D., Tchekmedyian N. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial // Cancer. – 2004; 100: 2613.
  8. Rosen L., Gordon D., Kaminski M. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial // Cancer J. – 2001; 7: 377.
  9. Berenson J., Hillner B., Kyle R. et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma // J. Clin. Oncol. – 2002; 20: 3719.
  10. Physicians' Desk Reference. 5710. th ed. Montvale / NJ: Medical Economics, 2003.
  11. Letocha A., Cintas H., Troendle J. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement // J. Bone Miner. Res. – 2005; 20: 977.
  12. Watts N. Bisphosphonate treatment of osteoporosis // Clin. Geriatr. Med. – 2003; 19: 395.
  13. Delmas P. The use of bisphosphonates in the treatment of osteoporosis // Curr. Opin. Rheumatol. – 2005; 17: 462.
  14. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic // J. Oral Maxillofac. Surg. – 2003; 61: 1115–7.
  15. Ruggiero S., Mehrotra B., Rosenberg T. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases // J. Oral Maxillofac. Surg. – 2004; 62: 527–34.
  16. Bagan J., Murillo J., Jimenez Y. et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases // J. Oral Pathol. Med. – 2005; 34: 120–3.
  17. Marx R., Sawatari Y., Fortin M. et al. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment // J. Oral Maxillofac. Surg. – 2005; 63: 1567–75.
  18. Durie B., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates // N. Engl. J. Med. – 2005; 353: 99–102
  19. Bennett C., Nebeker J., Lyons E. et al. The Research on Adverse Drug Events and Reports (RADAR) project // JAMA. – 2005; 293: 2131–40.
  20. Qi W., Tang L., He A. et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials // Int. J. Clin. Oncol. – 2013; 19 (2): doi: 10.1007/s10147-013-0561-6.
  21. Scagliotti G., Hirsh V., Siena S. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study // J. Thorac. Oncol. – 2012; 7: 1823.
  22. Ruzin G.P., Tkachenko O.V. Kliniko-rentgenologicheskie varianty techenija osteomielita kostej litsa u narkozavisimyh bol'nyh // Ukraїns'kij stomatologіchnij al'manah. – 2013; 1: 46–50.
  23. Nesterov A.P., Nesterov A.A., Habibov Ja.T. Patogenez odontogennogo osteomielita cheljustej u lits s zavisimost'ju ot dezomorfina // Dental Jug. – 2012; 102 (6): 42–4.
  24. Barannik N.G., Varzhapetjan S.D., Mosejko A.A. i dr. Opyt lechenija patsientov s osteomielitom cheljustej i vtorichnym immunodefitsitom na fone priema narkoticheskih preparatov. Aktual'nі pitannja medichnoї nauki ta praktiki: Zb. nauk. pr. DZ «ZMAPO MOZ Ukraїni». Zaporіzhzhja. 2013; 1 (1) Vyp. 80: 12–20.
  25. Mostovoj S.O., Ostapenko O.V., Shul'gin V.F. Identifikatsija etiologicheskogo faktora, vyzyvajuschego «vintovye osteomility», i otsenka ego vozdejstvija na kostnuju tkan' i mochevidelitel'nuju sistemu laboratornyh belyh krys // Uchenye zapiski Tavricheskogo natsional'nogo universiteta im. V.I. Vernadskogo Serija «Biologija, himija». – 2012; 25 (64): 244–51.
  26. Marx R. Uncovering the cause of «phossy jaw» circa 1858 to 1906: Oral and maxillofacial surgery closed case file – Case closed // J. Oral. Maxillofac. Surg. – 2008; 66: 2356.